ELVN
Enliven Therapeutics Inc

1,245
Mkt Cap
$898.52M
Volume
562,289.00
52W High
$24.64
52W Low
$13.30
PE Ratio
-8.20
ELVN Fundamentals
Price
$15.50
Prev Close
$15.14
Open
$15.26
50D MA
$19.37
Beta
1.41
Avg. Volume
774,297.00
EPS (Annual)
-$1.89
P/B
1.88
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $84,200.00 in Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an...
MarketBeat·14d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction dated Friday, December 19th. The stock was sold...
MarketBeat·15d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1% - Here's What Happened
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 6.1% - What's Next...
MarketBeat·15d ago
News Placeholder
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN
5AM Venture Management LLC reduced its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 41.6% in the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·26d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,663 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average...
MarketBeat·27d ago
News Placeholder
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules PR Newswire BOULDER...
PR Newswire·27d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% on Insider Selling...
MarketBeat·27d ago
News Placeholder
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,663 Shares of Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,663 shares of the company's stock in a transaction on Monday, December 8th. The stock was sold at an average price of...
MarketBeat·27d ago
News Placeholder
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development Enliven Therapeutics Announces New CEO to Drive Next Phase of Development PR Newswire BOULDER, Colo., Dec. 11, 2025 Rick...
PR Newswire·27d ago
<
1
2
...
>

Latest ELVN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.